Table 3.
Performance of MRCP-derived metrics for the prediction of adverse outcomes.
| AUROC (95% CI) | Cut-off | SE (%) | SP (%) | |
|---|---|---|---|---|
| Median diameter | 0.787 (0.684–0.890) p <0.001 | 2.5 mm | 79.2 | 68.9 |
| Duct median range 1–3 mm | 0.219 (0.112–0.325) p <0.001 | 65% | 62.5 | 17.0 |
| Duct median range 3–5 mm | 0.783 (0.679–0.886) p <0.001 | 26% | 75.0 | 72.7 |
| Max dilatation diameter | 0.652 (0.528–0.776) p = 0.034 | 7.8 mm | 83.3 | 47.2 |
| Max absolute dilatation severity | 0.649 (0.524–0.774) p = 0.037 | 4.1 mm | 70.8 | 62.3 |
| Max relative dilatation severity | 0.688 (0.564–0.812) p = 0.009 | 151.8 | 79.2 | 62.3 |
| Percentage of ducts with strictures or dilatations | 0.666 (0.540–0.792) p = 0.020 | 20.9 | 83.3 | 49.1 |
| Percentage of abnormal duct length | 0.684 (0.557–0.811) p = 0.01 | 12.8 | 75.0 | 66.5 |
ROC analysis was conducted. AUROC, area under the receiver operating curve; MRCP, magnetic resonance cholangiopancreatography; SE, sensitivity; SP, specificity.